Ames, IA, United States

Time filter

Source Type

Patent
Harrisvaccines, Inc. | Date: 2014-07-23

Compositions and methods of protecting aquatic invertebrates from disease is shown. In one embodiment, dsRNA or antisense RNA to a nucleic acid molecule of the disease-causing microorganism is prepared and delivered to the animal. In another embodiment, a nucleic acid molecule of the disease-causing microorganism is delivered to the animal. In another embodiment, the RNA or nucleic acid molecule is delivered to the animal by replicon particle. In a further embodiment, the protective molecule is delivered to the digestive tract of the animal. Protection from disease is obtained.


Patent
Harrisvaccines, Inc. | Date: 2012-10-23

Compositions and methods of protecting aquatic invertebrates from disease is shown. In one embodiment, dsRNA or antisense RNA to a nucleic acid molecule of the disease-causing microorganism is prepared and delivered to the animal. In another embodiment, a nucleic acid molecule of the disease-causing microorganism is delivered to the animal. In another embodiment, the RNA or nucleic acid molecule is delivered to the animal by replicon particle. In a further embodiment, the protective molecule is delivered to the digestive tract of the animal. Protection from disease is obtained.


Patent
Harrisvaccines, Inc. | Date: 2013-01-08

A method of quickly producing a vaccine for a biotype of pathogenic microorganism is described, where a nucleic acid molecule or fragment thereof is obtained from a biological sample from an animal exposed to the microorganism, a protective molecule is prepared based on the nucleic acid molecule of interest or fragment thereof, and administered to an animal which has been or is as risk of being exposed to the microorganism. A protective response to the biotype of the microorganism is obtained in the animal.


Patent
Harrisvaccines, Inc. | Date: 2011-10-19

A method of quickly producing a vaccine for a biotype of pathogenic microorganism is described, where a nucleic acid molecule or fragment thereof is obtained from a biological sample from an animal exposed to the microorganism, a protective molecule is prepared based on the nucleic acid molecule of interest or fragment thereof, and administered to an animal which has been or is as risk of being exposed to the microorganism. A protective response to the biotype of the microorganism is obtained in the animal.


Patent
Harrisvaccines, Inc. | Date: 2011-10-19

Compositions and methods of protecting aquatic invertebrates from disease is shown. In one embodiment, dsRNA or antisense RNA to a nucleic acid molecule of the disease-causing microorganism is prepared and delivered to the animal. In another embodiment, a nucleic acid molecule of the disease-causing microorganism is delivered to the animal. In another embodiment, the RNA or nucleic acid molecule is delivered to the animal by replicon particle. In a further embodiment, the protective molecule is delivered to the digestive tract of the animal. Protection from disease is obtained.


Grant
Agency: Department of Agriculture | Branch: | Program: SBIR | Phase: Phase II | Award Amount: 460.00K | Year: 2011

Currently there are no truly effective interventions or therapeutic treatments for White spot syndrome virus (WSSV) in farmed shrimp. Current production practices focus on pathogen exclusion by stocking specific pathogen free (SPF) larvae, decontamination and filtration of water to prevent pathogen introduction, and strict biosecurity at hatcheries and grow out pond sites. This is extremely challenging due to the prevalence of WSSV in estuarine waters in shrimp producing areas, resulting in devastating financial losses, even in SPF populations. WSSV was first discovered in 1992 after several outbreaks of a high mortality disease occurred in shrimp farms in Taiwan. Within a decade it has spread throughout the world and is now endemic in most shrimp producing areas. WSSV has a wide host range of over 50 separate species including all penaeids and crayfish. In the United States, a 2007 APHIS study showed that 66% of tested samples were positive and it has been declared endemic by the state veterinarian and OIE in the Louisiana freshwater crayfish population. The combined economic impact of WSSV in farmed shrimp is tremendous. It is estimated that Asia alone has lost over $6 billion since 1992, and the Americas about $1-2 billion since WSSV introduction in 1999 with countries such as Ecuador showing the greatest economic impact. In addition to the tremendous economic effect on shrimp production, there is a rising concern for an introduction of WSSV into native crustacean species. Avenues exist for the introduction of WSSV into naive species such as reprocessing of frozen emergency harvested product or animal movement. In addition, the United States possesses over 350 of the estimated 500 species worldwide of crayfish species. In North America, 65 out of the estimated 400 resident species are endangered and half of these are listed as needing protection. The outcome of the proposed project would be the first effective commercially available vaccines that protect against disease caused by WSSV in shrimp. Harrisvaccines intends to market vaccine to be used in two different shrimp production settings. First, an injectable vaccine for adult breeding females will be targeted to SPF production companies and larger integrated intensive shrimp producers abroad who possess their own hatcheries for the purpose of restocking their ponds. The second would be an orally administered vaccine for post larvae (PL) shrimp that would aid in protection of the shrimp prior to entry into the ponds. This accomplishes disease prevention in the hatcheries as well as the ponds. The goal is to prevent disease that can cause increases in the variable costs of raising shrimp. In addition to the observable clinical signs of disease, WSSV is directly responsible for a reduction of feed conversion rates which result in increased feed costs and a reduction in harvest weight combined with 70-100% mortality. The costs associated with restocking ponds lost to disease add to this devastation. A vaccine against WSSV is undoubtedly a valuable insurance for the investment of shrimp rearing.


Grant
Agency: Department of Agriculture | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 99.33K | Year: 2014

Currently available vaccines for infectious bovine keratoconjunctivitis (IBK), also known as "pinkeye", have poor efficacy and low cross-protection between strains. This may be partly due to the lack of mucosal antibody responses, which are not induced by traditional inactivated bacterin vaccines. The use of alphavirus replicon particle (RP) vaccines has been shown to induce muscosal immune responses, while maintaining the safety profile of inactivated vaccines. The successful development of RP-based vaccines for IBK would allow for numerous improvements over the status quo, including:1. reduced animal welfare issues related to IBK;2. improved productivity and economic performance of disease-free animals;3. reduced antimicrobial usage, especially off-label prophylactic usage;4. enhanced food security.This project will develop RP-based vaccine candidates using previously-identified protective antigens and confirm their suitability for develoment using establighed laboratory techniques. These candidate vaccines will then be tested to confirm that mucosal antibody responses are generated against these antigens. Success in this project will enable further development and commercialization of next generation vaccines for IBK.


Patent
Harrisvaccines, Inc. | Date: 2015-02-17

A method of quickly producing a vaccine for a biotype of pathogenic microorganism is described, where a nucleic acid molecule or fragment thereof is obtained from a biological sample from an animal exposed to the microorganism, a protective molecule is prepared based on the nucleic acid molecule of interest or fragment thereof, and administered to an animal which has been or is as risk of being exposed to the microorganism. A protective response to the biotype of the microorganism is obtained in the animal.


Patent
Harrisvaccines, Inc. | Date: 2012-10-23

A method of quickly producing a vaccine for a biotype of pathogenic microorganism is described, where a nucleic acid molecule or fragment thereof is obtained from a biological sample from an animal exposed to the microorganism, a protective molecule is prepared based on the nucleic acid molecule of interest or fragment thereof, and administered to an animal which has been or is as risk of being exposed to the microorganism. A protective response to the biotype of the microorganism is obtained in the animal.


Grant
Agency: Department of Agriculture | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 79.70K | Year: 2010

WSSV is the most serious disease in farmed marine shrimp causing considerable financial losses throughout the last decade across the globe. It infects a wide variety of crustacean hosts including numerous species of wild and cultured marine shrimp, crayfish, and prawns. Although a multitude of vaccination strategies have been attempted with mixed results, no viable commercial product exists on the market. Our preliminary data demonstrate that Alphavirus replicon particles (RP) and a Sindbis (SIN) virus vector infect and express green fluorescent protein in shrimp following injection. Evidence also exists in other invertebrates that oral exposure through immersion has been a successful challenge model with other Alphaviruses. It is proposed that utilizing alphaviruses or alphavirus replicon particles would provide an effective platform for gene expression for mass WSSV vaccination of farmed shrimp.

Loading Harrisvaccines, Inc. collaborators
Loading Harrisvaccines, Inc. collaborators